T he Breast Cancer Prevention Trial, a placebocontrolled randomized clinical trial of chemo-
prophylaxis, was announced in April 1992. This program of the National Surgical Adjuvant …

In 1991, my National Surgical Adjuvant Breast and Bowel Project (NSABP) colleagues and I
concluded that enough biological and clinical data were available to provide justification for …

Fisher et al.(1) demonstrate a statistically significant reduction in the incidence of invasive
and noninvasive cancers of the breast associated with tamoxifen use. There was a …

The tamoxifen chemoprevention trial in health women is ongoing in over 250 cancer
treatment centers. The use of tamoxifen for the treatment of postmenopausal women with …

The tamoxifen Breast Cancer Prevention Trial (BCPT) is a randomized, double-blind,
placebo-controlled clinical trial to test the effectiveness of 20 mg of tamoxifen versus placebo …

An increasing body of data suggests that tamoxifen can suppress development of preclinical
breast cancer. Newer data in postmenopausal women also demonstrate major biologic …

A woman with breast cancer is put in the unenviable position of having to decide which of
the treatment regimes she is willing to undergo in order to achieve arrest of her disease …

Tamoxifen has been shown to reduce the risk of contra-lateral breast cancers in women by
about 40%[Early Breast Cancer Triallists' Collaborative Group E. Lancet 1992, 339, 1–15] …

Tamoxifen a synthetic antiestrogen, has been used in the treatment of all stages of breast
cancer. The National Surgical Adjuvant Breast and Bowel Project (NSABP) is now in the …

Synthesized in 1966 and initially tested as a potential contraceptive, the nonsteroidal
antiestrogen tamoxifen was subsequently found to have therapeutic benefits in the therapy …